Nurix Therapeutics (NRIX) Price & Analysis

Compare

462 Followers

NRIX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$8.18 - $29.56

Previous CloseN/A

Volume302.00K

Average Volume (3M)841.65K

Market Cap

$645.23M

Enterprise Value$457.82M

Total Cash (Recent Filing)$485.78M

Total Debt (Recent Filing)$51.93M

Price to Earnings (P/E)―

Beta2.19

Next Earnings

Oct 09, 2025

EPS Estimate

-0.82

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.52

Shares Outstanding76,449,356

10 Day Avg. Volume1,042,133

30 Day Avg. Volume841,655

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.71

Enterprise Value/Revenue5.18

Enterprise Value/Gross Profit5.73

Enterprise Value/Ebitda-2.10

Forecast

1Y Price Target

$28.77

Price Target Upside240.88% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering13

Bulls Say, Bears Say

Bulls Say

Cash PositionNurix ended F2Q25 with ~$485.8M in cash and cash equivalents, providing an operational runway into 1H27.

Clinical TrialsThe data demonstrated continued deepening of responses over time in the CLL cohort, with an overall response rate reaching 81% across all dose levels tested, and no new safety signals identified.

EarningsNurix reported $44.1M in collaboration/license revenue, exceeding previous estimates of $25.0M.

Bears Say

Competitive RisksThe stock is not expected to perform well until there is clinical differentiation versus BGB-16673, clarity on a time- and capital-efficient development path, and/or a value-driving strategic partnership.

Operating ExpensesAnalyst slightly lowers the 12-month price target to $34 from $36 due to greater operating expenses.

Regulatory UncertaintyShares are down -35% as investors await clarity on the future regulatory strategy for bexdeg in CLL.

Nurix Therapeutics News

Nurix Therapeutics presents data from GS-6791

Nurix Therapeutics (NRIX) announced the presentation of preclinical data from GS-6791/NX-0479, a novel IRAK4 protein degrader discovered as...

5d ago

GILD

NRIX

Nurix Therapeutics to Discuss Bexobrutideg Developments

Nurix Therapeutics ( ($NRIX) ) has issued an update. Nurix Therapeutics announced plans to meet with securities analysts...

19d ago

NRIX

Nurix Therapeutics Announces Leadership Change in Committee

Nurix Therapeutics ( ($NRIX) ) has provided an announcement. On August 19, 2025, Nurix Therapeutics announced that Lori...

1M ago

NRIX

Nurix Therapeutics price target lowered to $30 from $32 at Oppenheimer

Oppenheimer lowered the firm’s price target on Nurix Therapeutics (NRIX) to $30 from $32 and keeps an Outperform...

2M ago

NRIX

Nurix Therapeutics price target lowered to $16 from $17 at Morgan Stanley

Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Nurix Therapeutics (NRIX) to $16 from $17...

2M ago

NRIX

Buy Rating for Nurix Therapeutics Driven by Strong Financials and Upcoming Clinical Milestones

Analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Nurix Therapeutics, reducing the price target to...

2M ago

NRIX

Nurix Therapeutics price target lowered to $34 from $36 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Nurix Therapeutics (NRIX) to $34 from $36 and keeps a...

2M ago

NRIX

Top 3 Trending Stocks, According to Analysts – 7/11/2025

Wondering which stocks are trending today? TipRanks has calculated which stocks have received the greatest number of new...

2M ago

NRIX

RARE

Optimistic Buy Rating for Nurix Therapeutics Amid Regulatory and Strategic Catalysts

Analyst Derek Archila from Wells Fargo reiterated a Buy rating on Nurix Therapeutics and keeping the price target...

2M ago

NRIX

Nurix Therapeutics price target lowered to $30 from $32 at Oppenheimer

Oppenheimer analyst Matthew Biegler lowered the firm’s price target on Nurix Therapeutics (NRIX) to $30 from $32 and...

2M ago

NRIX

Nurix Therapeutics: Strategic Advancements and Promising Pipeline Drive Buy Rating

In a report released yesterday, Jeet Mukherjee from BTIG maintained a Buy rating on Nurix Therapeutics, with a...

2M ago

NRIX

Positive Outlook for Nurix Therapeutics: Strong Financials and Promising Clinical Progress Support Buy Rating

Analyst Gil Blum of Needham maintained a Buy rating on Nurix Therapeutics, retaining the price target of $27.00....

2M ago

NRIX

Nurix Therapeutics price target lowered to $26 from $30 at UBS

UBS lowered the firm’s price target on Nurix Therapeutics (NRIX) to $26 from $30 and keeps a Buy...

2M ago

NRIX

Nurix Therapeutics Reports Increased Revenue Amid Net Loss

Nurix Therapeutics, Inc. ( ($NRIX) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

NRIX

NRIX FAQ

What was Nurix Therapeutics’s price range in the past 12 months?

Nurix Therapeutics lowest stock price was $8.18 and its highest was $29.56 in the past 12 months.

What is Nurix Therapeutics’s market cap?

Nurix Therapeutics’s market cap is $645.23M.

When is Nurix Therapeutics’s upcoming earnings report date?

Nurix Therapeutics’s upcoming earnings report date is Oct 09, 2025 which is in 17 days.

How were Nurix Therapeutics’s earnings last quarter?

Nurix Therapeutics released its earnings results on Jul 09, 2025. The company reported -$0.52 earnings per share for the quarter, beating the consensus estimate of -$0.719 by $0.199.

Is Nurix Therapeutics overvalued?

According to Wall Street analysts Nurix Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Nurix Therapeutics pay dividends?

Nurix Therapeutics does not currently pay dividends.

What is Nurix Therapeutics’s EPS estimate?

Nurix Therapeutics’s EPS estimate is -0.82.

How many shares outstanding does Nurix Therapeutics have?

Nurix Therapeutics has 76,449,356 shares outstanding.

What happened to Nurix Therapeutics’s price movement after its last earnings report?

Nurix Therapeutics reported an EPS of -$0.52 in its last earnings report, beating expectations of -$0.719. Following the earnings report the stock price went down -3.869%.

Which hedge fund is a major shareholder of Nurix Therapeutics?

Currently, no hedge funds are holding shares in NRIX

Nurix Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-50.67%

Trailing 12-Months

Asset Growth

15.76%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Nurix Therapeutics

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.

Nurix Therapeutics (NRIX) Earnings & Revenues

Historic Earnings Reports

NRIX Stock 12 Month Forecast

Average Price Target

$28.77

▲(240.88% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","37":"$37","15.25":"$15.25","22.5":"$22.5","29.75":"$29.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":36,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$36.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28.77,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$28.77</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,15.25,22.5,29.75,37],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.11,11.178461538461537,13.246923076923077,15.315384615384616,17.383846153846154,19.45230769230769,21.520769230769233,23.58923076923077,25.657692307692308,27.726153846153846,29.794615384615383,31.863076923076925,33.931538461538466,{"y":36,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.11,10.622307692307691,12.134615384615383,13.646923076923077,15.159230769230769,16.67153846153846,18.183846153846154,19.696153846153848,21.20846153846154,22.72076923076923,24.233076923076922,25.745384615384616,27.25769230769231,{"y":28.77,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.11,9.639999999999999,10.17,10.7,11.23,11.76,12.29,12.82,13.35,13.879999999999999,14.41,14.94,15.469999999999999,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":25.2,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.09,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.47,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.49,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.84,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.71,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.45,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.47,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.16,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.71,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.04,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.11,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >